BPMX Tops Q2 EPS by 7c September 14, 2015 4:48
Post# of 223
Posted On: 09/14/2015 9:59:51 PM
BPMX Tops Q2 EPS by 7c
September 14, 2015 4:48 PM
BioPharmX (: BPMX) reported Q2 EPS of ($0.22), $0.07 better than the analyst estimate of ($0.29).
Management Overview and Recent Business Developments
Beyond its first commercially available product, Violet iodine, BioPharmX Corporation is also pursuing the development of novel products targeting large dermatologic markets. These include:
BPX01
BPX01, the Company's topical acne drug, will deliver minocycline in a directly applied, gel-like treatment that effectively treats acne, but with fewer expected side effects than its oral counterpart. The Company expects to file an IND with the FDA for BPX01 and currently anticipates Phase 2 (505)(b) clinical trials to commence in early 2016. In the coming months the Company plans to release key data on its acne product that it anticipates presenting at various dermatology events and conferences.
BPX02
BPX02 is still in research mode as the Company continues to make progress in the development of a prescription drug formulating biologics materials for a dermatology application.
BPX03 and Violet Iodine
BPX03, the Company's prescription strength molecular iodine product that complements its Violet iodine product, is in development and the company plans to complete a multi-site IRB study over the next 12 months in preparation for Phase 3 trials. Phases 1 and 2 of these trials have already been completed. Both the Violet iodine supplement and BPX03 are uniquely formulated for the treatment of fibrocystic breast condition as well as overall breast health.
September 14, 2015 4:48 PM
BioPharmX (: BPMX) reported Q2 EPS of ($0.22), $0.07 better than the analyst estimate of ($0.29).
Management Overview and Recent Business Developments
Beyond its first commercially available product, Violet iodine, BioPharmX Corporation is also pursuing the development of novel products targeting large dermatologic markets. These include:
BPX01
BPX01, the Company's topical acne drug, will deliver minocycline in a directly applied, gel-like treatment that effectively treats acne, but with fewer expected side effects than its oral counterpart. The Company expects to file an IND with the FDA for BPX01 and currently anticipates Phase 2 (505)(b) clinical trials to commence in early 2016. In the coming months the Company plans to release key data on its acne product that it anticipates presenting at various dermatology events and conferences.
BPX02
BPX02 is still in research mode as the Company continues to make progress in the development of a prescription drug formulating biologics materials for a dermatology application.
BPX03 and Violet Iodine
BPX03, the Company's prescription strength molecular iodine product that complements its Violet iodine product, is in development and the company plans to complete a multi-site IRB study over the next 12 months in preparation for Phase 3 trials. Phases 1 and 2 of these trials have already been completed. Both the Violet iodine supplement and BPX03 are uniquely formulated for the treatment of fibrocystic breast condition as well as overall breast health.
(0)
(0)